The FDA’s Proposed Kratom Ban is a Mistake
AUGUST 29, 2021
T rust in the U.S. Food and Drug Administration (FDA) declined after its approval of the controversial Alzheimer’s drug aducanumab. Three experts resigned amid allegations that the FDA had caved to industry pressure. Some argue that its credibility has reached a new low.